Literature DB >> 12584533

Health values of adolescents with cystic fibrosis.

Michael S Yi1, Maria T Britto, Robert W Wilmott, Uma R Kotagal, Mark H Eckman, Dennis W Nielson, Vikki L Kociela, Joel Tsevat.   

Abstract

OBJECTIVES: To assess health values (utilities) in adolescents with cystic fibrosis (CF) and to evaluate how health status and clinical factors affect their health values.
METHODS: Adolescents 12 to 18 years of age completed the Child Health Questionnaire (CHQ), Health Utilities Index Mark 2 (HUI2), and 3 health value measures: the visual analog scale (VAS), time tradeoff (TTO), and standard gamble (SG). Severity of illness was measured by percent of predicted forced expiratory volume in 1 second (FEV(1)) and frequency of pulmonary exacerbations.
RESULTS: The mean age (+/- SD) of the 65 adolescents was 15.1 (+/- 2.1) years; 53.8% were male; their mean FEV(1) was 72.8% (+/- 27.0%) predicted. The mean TTO utility was 0.96 (+/- 0.07) and the mean SG utility was 0.92 (+/- 0.15). In multivariable analysis, the General Health Perceptions domain from the CHQ was the only health status scale significantly associated with the VAS, TTO, and SG. No clinical or demographic measures were significantly related to both TTO and SG scores.
CONCLUSIONS: Direct utility assessment in adolescents with CF is feasible. Their TTO and SG utilities are generally high, indicating that they are willing to trade very little of their life expectancy or take more than a small risk of death to obtain perfect health. Their self-rated health perceptions are related to their health values, but, as in adult populations, only moderately so, indicating that health values are highly individualistic. Therefore, health values should be ascertained directly from adolescents.

Entities:  

Mesh:

Year:  2003        PMID: 12584533     DOI: 10.1067/mpd.2003.51

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  17 in total

1.  Health values of patients coinfected with HIV/hepatitis C: are two viruses worse than one?

Authors:  Joseph M Mrus; Kenneth E Sherman; Anthony C Leonard; Susan N Sherman; Karen L Mandell; Joel Tsevat
Journal:  Med Care       Date:  2006-02       Impact factor: 2.983

2.  Predictors of risk tolerance among oral surgery patients.

Authors:  Kathryn A Atchison; Claudia Der-Martirosian; Thomas R Belin; Edward E Black; Melanie W Gironda
Journal:  J Oral Maxillofac Surg       Date:  2010-08-03       Impact factor: 1.895

3.  Quality of life and congenital heart defects: comparing parent and professional values.

Authors:  Rachel L Knowles; Ingolf Griebsch; Catherine Bull; Jacqueline Brown; Christopher Wren; Carol Dezateux
Journal:  Arch Dis Child       Date:  2006-05-31       Impact factor: 3.791

4.  Preferences for type 2 diabetes health states among adolescents with or at risk of type 2 diabetes mellitus.

Authors:  Erinn T Rhodes; Lisa A Prosser; Tracy A Lieu; Thomas J Songer; David S Ludwig; Lori M Laffel
Journal:  Pediatr Diabetes       Date:  2011-04-13       Impact factor: 4.866

5.  The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis.

Authors:  Paul Tappenden; Sue Harnan; Lesley Uttley; Matthew Mildred; Martin Walshaw; Christopher Taylor; Keith Brownlee
Journal:  Pharmacoeconomics       Date:  2014-02       Impact factor: 4.981

6.  The cost-effectiveness of palivizumab in infants with cystic fibrosis in the Canadian setting: A decision analysis model.

Authors:  Ashleigh A McGirr; Kevin L Schwartz; Upton Allen; Melinda Solomon; Beate Sander
Journal:  Hum Vaccin Immunother       Date:  2016-10-21       Impact factor: 3.452

Review 7.  A Review of the Development and Application of Generic Multi-Attribute Utility Instruments for Paediatric Populations.

Authors:  Gang Chen; Julie Ratcliffe
Journal:  Pharmacoeconomics       Date:  2015-10       Impact factor: 4.981

Review 8.  The generation gap: differences between children and adults pertinent to economic evaluations of health interventions.

Authors:  Ron Keren; Susmita Pati; Chris Feudtner
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

9.  Health status versus utilities of patients with end-stage liver disease.

Authors:  Cindy L Bryce; Derek C Angus; JoAnn Switala; Mark S Roberts; Joel Tsevat
Journal:  Qual Life Res       Date:  2004-05       Impact factor: 4.147

10.  Health status in young adults two decades after pediatric liver transplantation.

Authors:  S Mohammad; L Hormaza; K Neighbors; P Boone; M Tierney; R K Azzam; Z Butt; E M Alonso
Journal:  Am J Transplant       Date:  2012-05-08       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.